The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

David A. Bond, MD, assistant professor, The Ohio State University, discusses the high rates of second cancers in both treatment-naïve and pretreated patients with chronic lymphocytic leukemia who received BTK inhibitors.

The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels—from prevention to treatment and survivorship.

Financial pledge from Pelotonia represents one of the largest gifts ever to The Ohio State University and honors the 2,265 riders who participated in the inaugural ride in 2009.

Jennifer Woyach, MD, discusses a 3-year follow-up looking at acalabrutinib with obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses the 3-year follow-up from the single-arm study of the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia and the future of treatment in the space.

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

David O'Malley, MD, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Symptoms of burnout continue to plague the physician community overall, but a recent survey suggests that factors such as resiliency and the ability to flourish can diminish its detrimental effects.

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia.

David O'Malley, MD, gynecologic oncologist and an assistant professor in the Department of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of rucaparib (Rubraca)

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the future treatment of patients with chronic lymphocytic leukemia (CLL).

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in the treatment of patients with ovarian cancer.

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in ovarian cancer.

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma.